• search

EC approves use of insulin drug "NovoRapid"

Written by: Staff

Chennai, Oct 26 (UNI) There is new hope of succour for women suffering from pregnancy diabetes with the European Commission (EC) approving the use of insulin drug ''NovolRapid'' .

Thanks to an exhaustive study conducted by Novo Nordisk, proving the safety and efficacy of the drug, the European Commission has given its nod for its use by pregnant women with diabetes, Dr Anil Shinde, Medical Director, Novo Nordisk India Private Limited said.

He said the company had conducted the study, involving 322 pregnant women with type I diabetes spread over in 70 countries in 90 different hospitals over the last four years.

The Regulatory Commission of EU gave its approval in July after it was established that NovoRapid significantly improved first and third trimsters postprandial glycaemic control as compared to human insulin, he said.

''Thus, NovoRapid has emerged as the first modern insulin that has a label stating it can be used in pregnancy'', he said.

After the Drug Controller General of India (DGCI) gave its approval, the drug was available in the market for the last three years as an insulin drug for generally affected diabetes.

However, now with the onset of the landmark study and its approval from the Erupean Commission, the drug is recommended for women suffering from pregnancy related diabetes, he said.

Citing a World Health Organisation (WHO) study, Dr Shinde said prevelance of Gestational Diabetes Mellitus (GDM-defined as any degree of glucose intolerence during pregnancy) in Indian women was nearly 17 per cent and is growing.

He said there would be 80 million women in reproductive age with diabetes in the world, including 20 million in India, in the next two to three decades.


For Daily Alerts

For Breaking News from Oneindia
Get instant news updates throughout the day.

Notification Settings X
Time Settings
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more